|New Threads Only:|
|New Threads & Replies:|
Forum List » Guru News and Commentaries|
Guru News, Stock picks and commentaries
Weekly Top Insider Sells： AAPL, GILD, BMRN, and PCLN
Posted by: gurugk (IP Logged)
Date: November 19, 2012 04:40PM
According to GuruFocus Insider Data, these are the largest insider sells during the past week. The overall trend of insiders is illustrated in the chart below:
Apple Inc. (AAPL): Senior Vice President Daniel J. Riccio sold 20,226 Shares
Senior Vice President of Apple Inc. (AAPL) Daniel J. Riccio sold 20,226 shares on 11/16/2012 at an average price of $528.88.
Apple Inc. is engaged in designing, manufacturing and marketing mobile communication and media devices, personal computers, and portable digital music players. Apple Inc has a market cap of $494.65 billion; its shares were traded at around $528.88 with a P/E ratio of 11.95 and P/S ratio of 3.16. The dividend yield of Apple Inc stocks is 2.01%. Apple Inc. had an annual average earnings growth of 79.5% over the past 10 years. GuruFocus rated Apple Inc. the business predictability rank of 4.5-star.
On Oct. 25, 2012, Apple Inc. announced financial results for its fiscal 2012 fourth quarter ended Sept. 29, 2012. The company posted quarterly revenue of $36.0 billion and quarterly net profit of $8.2 billion, or $8.67 per diluted share. These results compare to revenue of $28.3 billion and net profit of $6.6 billion, or $7.05 per diluted share, in the year-ago quarter. Gross margin was 40.0 percent compared to 40.3 percent in the year-ago quarter.
Senior Vice President Jeffrey E. Williams sold 4,014 shares of AAPL stock on 10/16/2012 at the average price of 642.66. Jeffrey E. Williams owns at least 276 shares after this. The price of the stock has decreased by 17.7% since.
Gilead Sciences Inc. (GILD): Senior Vice President and CFO Robin L. Washington sold 111,900 Shares
Senior Vice President and CFO of Gilead Sciences Inc. (GILD) Robin L. Washington sold 111,900 shares during the past week at an average price of $74.4.
Gilead Sciences Inc. is an independent biopharmaceutical company that seeks to provide accelerated solutions for patients and the people who care for them. Gilead Sciences Inc. has a market cap of $56.29 billion; its shares were traded at around $74.4 with a P/E ratio of 21.75 and P/S ratio of 6.71. Gilead Sciences Inc. had an annual average earnings growth of 26.1% over the past 5 years.
On Oct. 23, 2012 Gilead Sciences Inc. announced its results of operations for the quarter ended September 30, 2012. Total revenues for the third quarter of 2012 increased 14 percent to$2.43 billion, from $2.12 billion for the third quarter of 2011. Net income for the third quarter of 2012 was $675.5 million, or $0.85 per diluted share compared to $741.1 million, or $0.95 per diluted share for the third quarter of 2011.
Director Etienne Davignon sold 20,000 shares of GILD stock on 10/26/2012 at the average price of $67.24. Etienne Davignon owns at least 582,934 shares after this. The price of the stock has increased by 10.65% since.
Biomarin Pharmaceutical Inc. (BMRN): Director Elaine J. Heron sold 136,875 Shares
Director of Biomarin Pharmaceutical Inc. (BMRN) Elaine J. Heron sold 136,875 shares during the past week at an average price of $48.
BioMarin Pharmaceutical Inc. is a developer of carbohydrate enzyme therapies for debilitating, life-threatening, chronic genetic disorders and other diseases and conditions. Biomarin Pharmaceutical Inc. has a market cap of $5.92 billion; its shares were traded at around $48 with and P/S ratio of 13.41.
BioMarin Pharmaceutical Inc. announced financial results for the second quarter of 2012. GAAP net loss was $32.0 million ($0.27 per share) for the second quarter of 2012, compared to GAAP net loss of $5.1 million ($0.05 per share) for the second quarter of 2011. Non-GAAP adjusted EBITDA was a loss of $7.3 million for the second quarter of 2012, compared to non-GAAP adjusted EBITDA gain of $13.9 million for the second quarter of 2011.
Director Alan Lewis sold 15,000 shares of BMRN stock on 11/07/2012 at the average price of $46.8. Alan Lewis owns at least 15,900 shares after this. The price of the stock has increased by 2.56% since.
Priceline.com Inc. (PCLN): Director Ralph Bahna sold 10,000 Shares
Director of Priceline.com Inc. (PCLN) Ralph Bahna sold 10,000 shares on 11/12/2012 at an average price of $614.78.
Priceline.com Incorporated has pioneered a unique e-commerce pricing system known as a "demand collection system" that enables consumers to use the Internet to save money on a wide range of products and services while enabling sellers to generate incremental revenue. Priceline.com Inc. has a market cap of $30.63 billion; its shares were traded at around $614.78 with a P/E ratio of 21.52 and P/S ratio of 7.03. Priceline.com Inc. had an annual average earnings growth of 53.5% over the past 10 years.
On Nov. 1, 2012, Priceline.com Incorporated reported third quarter 2012 financial results for the Priceline Group. Third quarter gross travel bookings for the Group, which refers to the total dollar value, generally inclusive of all taxes and fees, of all travel services purchased by consumers, were $7.8 billion, an increase of 25.2% over a year ago (approximately 34% on a local currency basis). The group had revenues in the third quarter of $1.7 billion, a 17.4% increase over a year ago.
HD Worldwide Strategy and Planning Glenn D. Fogel sold 1,000 shares of PCLN stock on 06/12/2012 at the average price of $641.03. Glenn D. Fogel owns at least 7,702 shares after this. The price of the stock has decreased by 4.09% since.
For the complete list of stocks that were bought/sold by their company executives, go to: Insider Buys.
Stocks Discussed: AAPL, GILD, BMRN, PCLN,
Disclaimers: GuruFocus.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The gurus may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.